Spinout Active LTD

Company profile

Hydregen Limited

HydRegen

Cleaner, safer, more efficient chemical manufacture. A spinout from the University of Oxford, commercialising a novel biotechnology. Our slot in technologies allow you to replace your heavy metal catalyst for hydrogenation reactions, or decarbonise existing redox biocatalysis processes all whilst operating within existing flow hydrogenation reactors.

CRN
13059070
Founded
2020
Age
5

Overview

Browse spinouts
Legal name
HYDREGEN LIMITED
Region
South East England
Registered address
30 UPPER HIGH STREET
THAME
ENGLAND
OX9 3EZ
Insolvency history
No

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
18

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

16 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

02 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

03 Dec
2020

Incorporated

Inception

Company registered at Companies House

Spinout profile

3 entries

Company description

HydRegen develops technology that enables companies to synthesise chemicals faster and at a lower cost.

HydRegen's biotechnology platform offers cleaner, safer, faster chemical manufacture, blending exquisite precision with efficient processing. HydRegen is a spin out of the University of Oxford, and holds an exclusive licence to a patent protecting a novel biotechnology (patent number: WO2013050760 A2, granted in EU and US). Our goal is to enable customers in the chemicals sector to replace toxic heavy metals, decarbonise biocatalysis and speed up adoption of flow processes. We will achieve this by: • selling R&D scale products that lower the barrier-to-entry for biocatalysis, • carrying out contract research for sale of tailored products, and • offering packages of product sales, contract research and technology licences for commercial processes We have secured £420k (Innovate UK and University Seed Challenge Fund) for 18 months of industrial research and development. We expect to launch our first commercial product within our first year, and to enter our first commercial licencing deal within 18 months.

Project impact

too early to state

HYDREGEN LIMITED
2020

Public funding

7 awards
First funded
2021
Funded years
2021, 2022, 2023, 2024, 2025
Age at first award
0 years

Projects

2025 Innovation Loans Lead participant

Bio2Amine: Scaling cost-competitive paracetamol production

17 Oct 2025 to 17 Oct 2028

Awarded
£2,000,000
Total cost £2,000,000

HydRegen is an early stage life-science start up committed to delivering next-generation manufacturing technologies that bridge between chemistry and biology, to fast-track cost and carbon competitive process that meet safety and sustainability requirements for UK manufacturing. Our technologies deliver 40% cost and 3xCO2e savings for manufacturing of che...

2025 Collaborative R&D Lead participant

Bio2Amine-Fampridine: delivering sustainable small molecule API manufacturing

1 Feb 2025 to 31 Jul 2026

Awarded
£515,891
Total cost £736,987

HydRegen is an early stage life-science start up committed to delivering next-generation manufacturing technologies that bridge between chemistry and biology, to fast-track cost and carbon competitive process that meet safety and sustainability requirements for UK manufacturing. Drochaid is a well-established industry specialist in catalyst screening, tes...

2024 EU-Funded Lead participant

Tungsten Biocatalysis - Heavy Metal Enzymes for Sustainable Industrial Biocatalysis

1 Feb 2024 to 31 Jan 2028

Awarded
£83,986
Total cost £83,986

Europe needs a sustainable chemical industry which will only be realized by new breakthrough technologies. Industrial biotechnology is established in chemical manufacturing, offering more efficient, more specific, safer and less energy demanding production, but is held back by the limited number of enzyme classes in industrial use. This project opens up a...

2023 Collaborative R&D Lead participant

Biocatalytic nitro-reductions in scalable continuous flow reactors: paracetamol case study

1 Oct 2023 to 30 Sep 2025

Awarded
£514,088
Total cost £734,412

**HydRegen vision:** The HydRegen technologies offer the potential for cleaner, safer, faster and cheaper chemical manufacture. Deep understanding of biology and chemistry allow the HydRegen team to select the best components from biology and use them to develop robust biotechnologies that solve real problems in the chemicals sectors. We expect our techno...

2023 Collaborative R&D Lead participant

Intensification of metallo-enzyme production to unlock sustainable biocatalytic hydrogenation

1 Jul 2023 to 31 Dec 2023

Awarded
£50,226
Total cost £71,751

**HydRegen** is a 2021 spin-out from the University of Oxford's Department of Chemistry. **Our vision:** The HydRegen technologies offer the potential for cleaner, safer, faster and cheaper chemical manufacture. Deep understanding of biology and chemistry allow the HydRegen team to select the best components from biology and use them to develop robust bio...

2022 Investment Accelerator Lead participant

Unlocking biocatalytic hydrogenation for bulk chemical manufacture

1 Jan 2022 to 31 Dec 2023

Awarded
£384,764
Total cost £549,663

**HydRegen** is a 2021 spin-out from the University of Oxford's Department of Chemistry. **Our vision:** The HydRegen technologies offer the potential for cleaner, safer, faster and cheaper chemical manufacture. We expect our technologies to play a part in the UK chemicals sector meeting ambitious Net Zero emissions targets (by 2050) and increasing adopti...

2021 Study Lead participant

HydRegen: a sustainable chemistry platform

1 Feb 2021 to 31 Jul 2022

Awarded
£299,740
Total cost £299,740

We have developed sustainable technologies that address unmet needs in the chemicals sector through academic research at the University of Oxford. Chemicals companies are interested in our technologies because they remove the need for toxic reagents, minimise the production of carbon-based waste products and lower energy demands compared to existing manuf...

Product types

Collaborative R&D EU-Funded Innovation Loans Investment Accelerator Study